Filed Pursuant to Rule 424(b)(2)
Registration No. 333-279084
The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED JUNE 4, 2024
Prospectus Supplement to Prospectus dated May 2, 2024
Becton, Dickinson and Company
$ % Notes due 20
We are offering $ aggregate principal amount of % Notes due 20 (the “notes”). Interest on the notes will be payable in cash semi-annually in arrears on and of each year, beginning on , 2024. The notes will mature on , 20 .
We may, at our option, redeem the notes, in whole or in part, at any time and from time to time, at the applicable redemption prices described in this prospectus supplement. See “Description of Notes—Optional Redemption.” In addition, if a change of control triggering event occurs as described in this prospectus supplement under the heading “Description of Notes—Offer to Repurchase Upon Change of Control Triggering Event,” unless we have exercised our right to redeem such notes as described under “Description of Notes—Optional Redemption,” we will be required to offer to purchase the notes from the holders.
Concurrently with this offering, we are also offering € aggregate principal amount of % Notes due 20 , and Becton Dickinson Euro Finance S.à r.l., which is our indirect, wholly-owned finance subsidiary (“BD Finance”), is offering € aggregate principal amount of its % Notes due 20 , which notes are fully and unconditionally guaranteed on a senior unsecured basis by us (collectively, the “concurrent offerings”). The closings of this offering and the concurrent offerings are not conditioned on each other. The concurrent offerings are being made by means of separate prospectus supplements and not by means of this prospectus supplement. This prospectus supplement is not an offer to sell or a solicitation of an offer to buy any securities being offered in the concurrent offerings.
We expect to use the net proceeds from this offering, together with proceeds from the concurrent offerings, borrowings under our commercial paper program and cash on hand, (i) to fund the cash consideration payable by us for the acquisition (the “Acquisition”) of the Critical Care business (the “Business”) of Edwards Lifesciences Corporation (“Seller Parent”) and its subsidiaries by us and/or certain of our subsidiaries, (ii) to pay fees and expenses in respect of the foregoing, and (iii) for general corporate purposes. This offering is not conditioned upon the consummation of the Acquisition, which, if completed, will occur subsequent to the closing of this offering, and we cannot assure you that the Acquisition will be consummated on the terms described herein, or at all. See “Summary—Recent Developments—The Acquisition” and “Use of Proceeds.”
If (i) the Acquisition is not consummated on or before the later of (x) June 3, 2025; and (y) the date that is five business days after any later date to which Seller Parent and we may agree to extend the “Outside Date” in the Acquisition Agreement (as defined below) (such later date, the “Special Mandatory Redemption End Date”) or (ii) we notify the trustee under the indenture that we will not pursue the consummation of the Acquisition, then we will be required to redeem the notes (the “Special Mandatory Redemption”) at a special mandatory redemption price equal to 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date (as defined herein) (subject to the right of holders of the notes of record on the relevant record date to receive interest due on an interest payment date falling prior to the Special Mandatory Redemption Date). The proceeds from this offering will not be deposited into an escrow account pending completion of the Acquisition or any Special Mandatory Redemption, nor will we be required to grant any security interest or other lien on those proceeds to secure any redemption of the notes. See “Description of Notes—Special Mandatory Redemption.”
The notes will be our senior unsecured obligations and will rank equally in right of payment with all of our other senior unsecured indebtedness, including our other outstanding senior notes. The notes will be issued in minimum denominations of $1,000 and in integral multiples of $1,000 in excess thereof.
The notes will not be listed on any securities exchange.
Investing in the notes involves risks that are described in the “Risk Factors” section of this prospectus supplement beginning on page S-
6 and in our latest Annual Report on Form 10-K, which is incorporated by reference into this prospectus supplement (as such risk factors may be updated from time to time in our public filings).
Neither the Securities and Exchange Commission (the “SEC”) nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the related prospectus. Any representation to the contrary is a criminal offense.
Notes
|
|
|
% |
|
|
$ |
|
|
% |
|
|
$ |
|
|
% |
|
|
$ |
Total
|
|
|
|
|
|
$ |
|
|
|
|
|
$ |
|
|
|
|
|
$ |
(1)
|
Plus accrued interest from June , 2024, if settlement occurs after that date. |
The underwriters expect to deliver the notes to purchasers in book-entry form only through the facilities of The Depository Trust Company (“DTC”), including its participants Clearstream Banking S.A. (“Clearstream”) and Euroclear Bank SA/NV (“Euroclear”), against payment in New York, New York on or about June , 2024.
Joint Book-Running Managers
Citigroup |
|
|
Barclays |
|
|
BNP PARIBAS |
|
|
J.P. Morgan |
|
|
Wells Fargo Securities |
The date of this prospectus supplement is June , 2024.